4 news items
Notable Labs Reports 2023 Financial Results and Provides a Business Update
NTBL
12 Apr 24
, with the goal of selectively enrolling and treating those predicted responders, increasing volasertib's response rates and overall patient outcomes, and fast
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
NTBL
9 Apr 24
in-licensing strategy and decision making, Notable will utilize PPMP to predict volasertib-responsive patients prior to their treatment, with the goal
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
NTBL
8 Apr 24
, including but not limited to, express or implied statements regarding Notable's future operations and goals; the potential benefits of any therapeutic
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
NTBL
5 Mar 24
, including but not limited to, express or implied statements regarding Notable's future operations and goals; the potential benefits of any therapeutic
- Prev
- 1
- Next